{
    "clinical_study": {
        "@rank": "6426", 
        "acronym": "CINEBENZ", 
        "arm_group": {
            "arm_group_label": "Benznidazole", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "o study population pharmacokinetics in Benznidazole-treated adult patients with Chronic\n      Chagas Disease to get information to optimize drug doses."
        }, 
        "brief_title": "Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease", 
        "condition": "Chagas Disease", 
        "condition_browse": {
            "mesh_term": "Chagas Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients with Chronic Chagas Disease diagnosed by 2 different and positive\n             serological tests.\n\n          -  Patients with Chronic Chagas Disease who are going to start treatment with\n             Benznidazole.\n\n          -  Any gender.\n\n          -  All the participants must agree to participate in the study and must sign the\n             informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients younger than 18.\n\n          -  Patients with previous hypersensitivity to Benznidazole.\n\n          -  Immunocompromised patients as AIDS, cancer, chemotherapy, longterm corticoids need,\n             primary immunodeficiency, or any other.\n\n          -  Hepatic dysfunction\n\n          -  Renal dysfunction: serum creatinin higher than 3 mg/dl.\n\n          -  Pregnancy or lactation.\n\n          -  Low adhesion to treatment or check-up.\n\n          -  Impossibility of follow-up.\n\n          -  Severe adverse reaction to Benznidazole.\n\n          -  Any other situation that could be risky for the patient."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755403", 
            "org_study_id": "CINEBENZ"
        }, 
        "intervention": {
            "arm_group_label": "Benznidazole", 
            "intervention_name": "Benznidazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Benzonidazole"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "state": "Catalu\u00f1a", 
                    "zip": "08036"
                }, 
                "name": "International Health Department, Hospital Clinic, Barcelona"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship.", 
        "overall_official": {
            "affiliation": "Barcelona Centre for International Health Research (CRESIB)", 
            "last_name": "Joaquim Gasc\u00f3n, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Population pharmacokinetic model development", 
            "measure": "Population pharmacokinetic parameters of Benznidazole", 
            "safety_issue": "No", 
            "time_frame": "2 months (treatment period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755403"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of participants with adverse events. Severity of adverse events. Relationship between adverse event and drug concentration.", 
            "measure": "Adverse reactions", 
            "safety_issue": "Yes", 
            "time_frame": "2 months (treatment period)"
        }, 
        "source": "Barcelona Centre for International Health Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Barcelona Centre for International Health Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}